Neuropace Operating Margin vs. Return On Asset

NPCE Stock  USD 10.66  0.96  9.90%   
Based on the measurements of profitability obtained from Neuropace's financial statements, Neuropace may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Neuropace's ability to earn profits and add value for shareholders.

Neuropace Operating Profit Margin

(0.44)

As of November 26, 2024, Price To Sales Ratio is expected to decline to 3.87. In addition to that, Days Sales Outstanding is expected to decline to 51.18. At present, Neuropace's Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Non Operating Income Net Other is expected to grow to about 1.5 M, whereas Operating Income is forecasted to decline to (28.5 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.580.7356
Significantly Down
Slightly volatile
For Neuropace profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neuropace to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neuropace utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neuropace's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neuropace over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Revenue Per Share
2.697
Quarterly Revenue Growth
0.282
Return On Assets
(0.15)
Return On Equity
(2.15)
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Neuropace Return On Asset vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Neuropace's current stock value. Our valuation model uses many indicators to compare Neuropace value to that of its competitors to determine the firm's financial worth.
Neuropace is rated below average in operating margin category among its peers. It is rated below average in return on asset category among its peers . At present, Neuropace's Operating Profit Margin is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuropace by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Neuropace Return On Asset vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Neuropace

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(0.20) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Neuropace

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.15
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Neuropace Return On Asset Comparison

Neuropace is currently under evaluation in return on asset category among its peers.

Neuropace Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Neuropace, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neuropace will eventually generate negative long term returns. The profitability progress is the general direction of Neuropace's change in net profit over the period of time. It can combine multiple indicators of Neuropace, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-5.5 M-5.7 M
Interest IncomeM3.2 M
Operating Income-27.2 M-28.5 M
Net Loss-33 M-34.6 M
Income Before Tax-33 M-34.6 M
Total Other Income Expense Net-5.8 M-6.1 M
Net Loss-42.4 M-44.5 M
Net Loss-33 M-34.6 M
Income Tax Expense1.4 M1.4 M
Non Operating Income Net Other1.4 M1.5 M
Change To Netincome12.5 M6.5 M
Net Loss(1.27)(1.34)
Income Quality 0.60  0.84 
Net Income Per E B T 1.30  1.39 

Neuropace Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Neuropace. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neuropace position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neuropace's important profitability drivers and their relationship over time.

Use Neuropace in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuropace position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuropace will appreciate offsetting losses from the drop in the long position's value.

Neuropace Pair Trading

Neuropace Pair Trading Analysis

The ability to find closely correlated positions to Neuropace could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuropace when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuropace - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuropace to buy it.
The correlation of Neuropace is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuropace moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuropace moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuropace can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Neuropace position

In addition to having Neuropace in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cigarettes Thematic Idea Now

Cigarettes
Cigarettes Theme
Tobacco makers and distributors across globe. The Cigarettes theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:
Check out Correlation Analysis.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
To fully project Neuropace's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neuropace at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neuropace's income statement, its balance sheet, and the statement of cash flows.
Potential Neuropace investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Neuropace investors may work on each financial statement separately, they are all related. The changes in Neuropace's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neuropace's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.